174 related articles for article (PubMed ID: 38799467)
1. Serum AXL is a potential molecular marker for predicting COVID-19 progression.
You J; Huang R; Zhong R; Shen J; Huang S; Chen J; Chen F; Kang Y; Chen L
Front Immunol; 2024; 15():1394429. PubMed ID: 38799467
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y
J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654
[TBL] [Abstract][Full Text] [Related]
4. Antibody tests for identification of current and past infection with SARS-CoV-2.
Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19.
Chiereghin A; Zagari RM; Galli S; Moroni A; Gabrielli L; Venturoli S; Bon I; Rossini G; Saracino IM; Pavoni M; Lafratta S; Deni A; Felici S; Borghi M; Guerra L; Raumer L; Lodi V; Viale P; Attard L; Lazzarotto T;
Front Public Health; 2020; 8():620222. PubMed ID: 33681115
[No Abstract] [Full Text] [Related]
6. Clinical significance of the serum IgM and IgG to SARS-CoV-2 in coronavirus disease-2019.
Wu LX; Wang H; Gou D; Fu G; Wang J; Guo BQ
J Clin Lab Anal; 2021 Jan; 35(1):e23649. PubMed ID: 33184940
[TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
Tré-Hardy M; Wilmet A; Beukinga I; Favresse J; Dogné JM; Douxfils J; Blairon L
J Med Virol; 2021 Feb; 93(2):803-811. PubMed ID: 32667733
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.
Infantino M; Grossi V; Lari B; Bambi R; Perri A; Manneschi M; Terenzi G; Liotti I; Ciotta G; Taddei C; Benucci M; Casprini P; Veneziani F; Fabbri S; Pompetti A; Manfredi M
J Med Virol; 2020 Sep; 92(9):1671-1675. PubMed ID: 32330291
[TBL] [Abstract][Full Text] [Related]
9. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients.
Wang Y; Li J; Li H; Lei P; Shen G; Yang C
Int Immunopharmacol; 2021 Jan; 90():107271. PubMed ID: 33310664
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
[TBL] [Abstract][Full Text] [Related]
11. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.
Wang S; Qiu Z; Hou Y; Deng X; Xu W; Zheng T; Wu P; Xie S; Bian W; Zhang C; Sun Z; Liu K; Shan C; Lin A; Jiang S; Xie Y; Zhou Q; Lu L; Huang J; Li X
Cell Res; 2021 Feb; 31(2):126-140. PubMed ID: 33420426
[TBL] [Abstract][Full Text] [Related]
12. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19.
Qin X; Shen J; Dai E; Li H; Tang G; Zhang L; Hou X; Lu M; Wu X; Duan S; Zhang J; Tsoi MF; Jiang P; Li Y
BMC Immunol; 2021 Feb; 22(1):14. PubMed ID: 33596826
[TBL] [Abstract][Full Text] [Related]
13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
14. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
Infantino M; Manfredi M; Grossi V; Lari B; Fabbri S; Benucci M; Fortini A; Damiani A; Mobilia EM; Panciroli M; Pancani S; Pesce G
J Med Virol; 2021 Mar; 93(3):1436-1442. PubMed ID: 32790181
[TBL] [Abstract][Full Text] [Related]
15. Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis.
Indenbaum V; Koren R; Katz-Likvornik S; Yitzchaki M; Halpern O; Regev-Yochay G; Cohen C; Biber A; Feferman T; Cohen Saban N; Dhan R; Levin T; Gozlan Y; Weil M; Mor O; Mandelboim M; Sofer D; Mendelson E; Lustig Y
PLoS One; 2020; 15(11):e0241164. PubMed ID: 33227020
[TBL] [Abstract][Full Text] [Related]
16. Plasma ACE2 species are differentially altered in COVID-19 patients.
García-Ayllón MS; Moreno-Pérez O; García-Arriaza J; Ramos-Rincón JM; Cortés-Gómez MÁ; Brinkmalm G; Andrés M; León-Ramírez JM; Boix V; Gil J; Zetterberg H; Esteban M; Merino E; Sáez-Valero J
FASEB J; 2021 Aug; 35(8):e21745. PubMed ID: 34191346
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
[TBL] [Abstract][Full Text] [Related]
18. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
Al-Mughales JA; Al-Mughales TJ; Saadah OI
Front Immunol; 2021; 12():705441. PubMed ID: 34539635
[TBL] [Abstract][Full Text] [Related]
19. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study.
Moradi G; Mohamadi Bolbanabad A; Ahmadi S; Aghaei A; Bahrami F; Veysi A; Nasiri Kalmarzi R; Shokri A; Ghaderi E; Mohsenpour B; Mohammadi A
Int Immunopharmacol; 2021 Sep; 98():107893. PubMed ID: 34174700
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
